Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EGFRvIII CAR-T (Guangzhou FineImmune Biotechnology)
- Development stage
- Preclinical
- Lead developer
- Guangzhou FineImmune Biotechnology
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
EGFRvIII CAR-T is an autologous chimeric antigen receptor (CAR) T-cell therapy developed by Guangzhou FineImmune Biotechnology for the treatment of glioblastoma. The therapy utilizes the company's SUPER CAR-T platform to engineer T cells that specifically target the Epidermal Growth Factor Receptor variant III (EGFRvIII), a tumor-specific mutation frequently expressed in glioblastoma multiforme but absent in healthy tissues. By binding to EGFRvIII-expressing cells, the CAR-T cells initiate targeted cytotoxicity to eliminate malignant cells while minimizing off-target effects on normal brain tissue.
- Other names
- EGFRvIII-targeted CAR-TEGFRvIII CAR-T cell therapy
02
Targets
EGFRvIII (Epidermal growth factor receptor variant III)
Beyond the preview
Go deeper on EGFRvIII CAR-T (Guangzhou FineImmune Biotechnology).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EGFRvIII CAR-T (Guangzhou FineImmune Biotechnology).